

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. DO NOT EXCEED FIVE PAGES.

NAME: Berger, Adam

eRA COMMONS USERNAME (credential, e.g., agency login): ACB130

POSITION TITLE: Chief of Melanoma and Soft Tissue Surgical Oncology

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE (if applicable)	END DATE MM/YYYY	FIELD OF STUDY
The University of Chicago, Chicago, IL	BA	06/1991	History and Philosophy of Science and Medicine
New York University School of Medicine, New York, NY	MD	05/1995	Medicine

A. Personal Statement

I am a Professor and Chief of the Melanoma and Soft Tissue Sarcoma Section at the Rutgers Cancer Institute of New Jersey. I completed my residency in surgery at the University of Maryland in 2002 after spending two years in the Surgery Branch of the National Cancer Institute from 1997-1999. I then completed a fellowship in surgical oncology at the Fox Chase Cancer Center from 2002-2004. I was at Thomas Jefferson University from 2004 to July 2019 where I was the Section Chief for Surgical Oncology and held various leadership positions including the chair of the Cancer Center Protocol Review Committee and prior to that, the head of the Data Safety and Monitoring Committee. While at Jefferson, I was recognized with Dean's Awards for both Excellence in Education and in Faculty Mentoring. My research interests include clinical trials for cancer, the formation of clinical databases and prospective evaluation of clinicopathologic prognostic factors for various malignancies. I have written several investigator-initiated clinical trials and been PI on numerous other trials in breast cancer, melanoma, and soft tissue sarcoma. At Rutgers, I oversee the Section of Melanoma and Sarcoma Surgical Oncology and the Cutaneous Oncology Clinical Trials Working Group and am the Associate Director for Shared Resources. As the Associate Director for Shared Resources, I am responsible for 8-10 core facilities that provide scientific support to cancer center members to facilitate cancer-related research. I work with shared resource directors and managers to ensure that they provide well-reviewed services that meet the needs of investigators, and to ensure that they stay within recommended budgets.

B. Positions, Scientific Appointments and Honors**Positions and Scientific Appointments**

2019 - Chief of Melanoma and Soft Tissue Surgical Oncology, Rutgers Cancer Institute of NJ
 2015 - 2019 Chair, Protocol Review Committee, Kimmel Cancer Center, Thomas Jefferson University
 2014 - 2019 Professor, Department of Surgery, Thomas Jefferson University
 2014 - 2017 Program Committee, Society of Surgical Oncology
 2013 - 2019 Editorial Board, Journal of Gastrointestinal Surgery
 2011 - 2015 Chair, Data Safety Monitoring Board, Kimmel Cancer Center
 2010 - 2019 Chief, Section of Surgical Oncology, Department of Surgery, Thomas Jefferson University
 2010 - 2012 Leadership Committee, Association for Academic Surgery
 2009 - 2014 Associate Professor, Department of Surgery, Thomas Jefferson University
 2009 - 2012 Editorial Board, Journal of Clinical Oncology
 2008 - 2010 Education Committee, Association for Academic Surgery
 2005 - 2014 Principal Investigator, American College of Surgeons Oncology Group, Thomas Jefferson University

2004 - 2008	Assistant Professor, Department of Surgery, Thomas Jefferson University
2002 - 2004	Fellowship in Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA
2002 - 2004	Residency in General Surgery, University of Maryland Medical Center, Baltimore, MD
1997 - 1999	Clinical Associate, Surgery Branch, National Cancer Institute, NIH, Bethesda, MD
1997 - 1999	Residency in General Surgery, University of Maryland Medical Center, Baltimore, MD
1995 - 1996	Internship in General Surgery, University of Maryland Medical Center, Baltimore, MD

Honors

2017	Dean's Award for Faculty Mentoring, Jefferson Medical College
2011	Dean's Award for Excellence in Education, Jefferson Medical College
2009	Cancer Liaison Physician Outstanding Performance Award for 2008, Commission on Cancer
2006	Appreciation Award for Outstanding Service, Kimmel Cancer Center
2005	Simon Kramer New Investigator Award, Radiation Therapy Oncology Group
2004	Fellow Travel Award, International Society of Gastrointestinal Oncology
2004	Young Oncologist Travel Grant Award, American Radium Society
2004	Fellow Travel Award, ASCO GI Symposium

C. Contribution to Science

- I have been involved in the multidisciplinary care of patients with malignant melanoma for many years. This includes prospective clinical trials, clinical outcomes research, and analysis of prognostic factors associated with melanoma survival. I am currently the PI on a multi-institution Phase II trial examining the use of adjuvant Nivolumab for high-risk Stage IIB and IICc melanoma patients which is funded by Bristol-Myers Squibb and currently accruing.
 - Berger AC**, Ollila DW, Christopher A, Kairys JC, Mastrangelo MJ, Feeney K, Dabbish N, Leiby B, Frank JA, Stitzenberg KB, Meyers MO. Patient Symptoms Are the Most Frequent Indicators of Recurrence in Patients with American Joint Committee on Cancer Stage II Melanoma. *J Am Coll Surg.* 2017 Apr;224(4):652-659. PubMed PMID: 28189663.
 - Berger AC**, Davidson RS, Poitras JK, Chabra I, Hope R, Brackeen A, Johnson CE, Maetzold DJ, Middlebrook B, Oelschlager KM, Cook RW, Monzon FA, Miller AR. Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients. *Curr Med Res Opin.* 2016 Sep;32(9):1599-604. PubMed PMID: 27210115.
 - Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, Wouters MWJM, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Rossi CR, Neves RI, Trocha SD, Wright F, Byrd DR, Matter M, Hsueh E, MacKenzie-Ross A, Johnson DB, Terheyden P, **Berger AC**, Huston TL, Wayne JD, Smithers BM, Neuman HB, Schneebaum S, Gershenwald JE, Ariyan CE, Desai DC, Jacobs L, McMasters KM, Gesierich A, Hersey P, Bines SD, Kane JM, Barth RJ, McKinnon G, Farma JM, Schultz E, Vidal-Sicart S, Hofer RA, Lewis JM, Scheri R, Kelley MC, Nieweg OE, Noyes RD, Hoon DSB, Wang HJ, Elashoff DA, Elashoff RM. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. *N Engl J Med.* 2017 Jun 8;376(23):2211-2222. PubMed Central PMCID: PMC5548388.
 - Moncrieff MD, Gyorki D, Saw R, Spillane AJ, Thompson JF, Peach H, Oudit D, Geh J, Dziewulski P, Wilson E, Matteucci P, Pritchard-Jones R, Olofsson Bagge R, Wright FC, Crampton N, Cassell O, Jallali N, **Berger A**, Kelly J, Hamilton S, Durrani A, Lo S, Paton E, Henderson MA. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. *Ann Surg Oncol.* 2018 Sep;25(9):2541-2549. PubMed Central PMCID: PMC6097739.
- Additionally, I have made substantial contributions to laboratory-based investigations on the treatment of patients with malignant melanoma either through cell culture-based assays or the provision of human tissue samples for ongoing research by the Aplin lab.

- a. Capparelli C, Purwin TJ, Heilman SA, Chervoneva I, McCue PA, **Berger AC**, Davies MA, Gershenwald JE, Krepler C, Aplin AE. ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. *Cancer Res.* 2018 Oct 1;78(19):5680-5693. PubMed Central PMCID: PMC6168374.
- b. Capparelli C, Rosenbaum S, **Berger AC**, Aplin AE. Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. *J Biol Chem.* 2015 Oct 2;290(40):24267-77. PubMed Central PMCID: PMC4591813.
- c. Hartsough EJ, Kugel CH 3rd, Vido MJ, **Berger AC**, Purwin TJ, Goldberg A, Davies MA, Schiewer MJ, Knudsen KE, Bollag G, Aplin AE. Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas *In Vivo* and *Ex Vivo*. *Mol Cancer Ther.* 2018 Jan;17(1):84-95. PubMed Central PMCID: PMC5752590.
- d. Vu HL, Rosenbaum S, Capparelli C, Purwin TJ, Davies MA, **Berger AC**, Aplin AE. MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. *J Invest Dermatol.* 2016 Feb;136(2):453-463. PubMed Central PMCID: PMC4789776.

Complete List of Published Work in My Bibliography:

<https://www.ncbi.nlm.nih.gov/myncbi/18EJ6DhN9zbUeN/bibliography/public/>